Intellimedix is an accelerated drug discovery company located at the Jacoby Group headquarters in Atlanta, GA. The company develops cutting edge technology and science to accelerate the discovery of treatments and cures for human diseases and to personalize medicine.
As part of their technology suite, Intellimedix has an Ion Proton System with next-generation gene sequencing capabilities. The high capacity, high accuracy, and low operating cost ($1,000/genome) of the Ion Proton sequencer allows Intellimedix to sequence significant samples of the population to identify novel genes that cause or modify specific diseases. The genes will then act as molecular targets for Intellimedix’s high-throughput in silico screening process. This process uses proprietary algorithms and supercomputing to screen millions of compounds and identify those that bind to the target genes. In addition to identifying novel compounds, Intellimedix uses the strategy of drug reprofiling, also known as drug re-tasking, drug repositioning, or therapeutic switching. Compounds that have already been approved by the FDA are screened to identify new potential uses for these drugs.
The compounds identified in the in silico process are then screened for efficacy and toxicity in in vitro and zebrafish models of the disease of interest using high-throughput tools. The compounds that show promising results in this phase will then be tested in mice and humans.